Skip to main content
SpringerLink
Log in

Overview of Clinical Experience of Pefloxacin in Gastrointestinal Infections

  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Summary

The course of a number of enteric infectious diseases can be shortened by appropriate antimicrobial therapy. The treatable causative agents may be suspected from the clinical presentation. The fluoroquinolones currently represent the drugs of choice for most of the treatable bacterial enteric infections. There is a low frequency of bacterial resistance to the fluoroquinolones and they have favourable pharmacological properties, including therapeutic concentrations of the drug in serum, intestinal tissue, the lumen of the gut, and leucocytes and mononuclear cells. These properties make the fluoroquinolones the treatment of choice for typhoid fever.

In limited trials, pefloxacin has been successfully used for the treatment of bacterial enteric infection and febrile dysenteric diarrhoea (caused by strains of Shigella and Salmonella), and typhoid fever. Future studies with pefloxacin are needed to determine the optimal dose and duration of treatment, and the indications relating to enteric infection, as well as the value and safety of the drug in paediatric populations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Haltalin KC, Nelson JD, Hinton LV, et al. Comparison of orally absorbable and nonabsorbable antibiotics in shigellosis: a double-blind study with ampicillin and neomycin. J Pediatr 1968; 72: 708–20

    Article  PubMed  CAS  Google Scholar 

  2. Carlson JR, Thornton SA, DuPont HL, et al. Comparative in vitro activities of ten antimicrobial agents against bacterial enteropathogens. Antimicrob Agents Chemother 1983; 24: 509–13

    Article  PubMed  CAS  Google Scholar 

  3. Murray BE. Resistance of Shigella, Salmonella, and other selected enteric pathogens to antimicrobial agents. Rev Infect Dis 1986; 8Suppl. 2: S172–81

    Article  PubMed  Google Scholar 

  4. DuPont HL, Reves RR, Galindo E, et al. Treatment of travellers’ diarrhea with trimethoprimlsulfamethoxazole and with trimethoprim alone. N Engl J Med 1982; 307: 841–4

    Article  PubMed  CAS  Google Scholar 

  5. DuPont HL. Quinolone antimicrobial agents in the management of bacterial enteric infections. In: Wolfson JS, Hooper DC, editors. Quinolone antimicrobial agents. Washington, DC: Am Soc Microbiol 1989: 167–76

    Google Scholar 

  6. DuPont HL. Nonfluid therapy and selected chemoprophylaxis of acute diarrhea. Am J Med 1985; 78Suppl. 6B: 81–90

    Article  CAS  Google Scholar 

  7. Cofsky RD, duBouchet L, Landesman SH. Recovery of norfloxacin in feces after administration of a single oral dose to human volunteers. Antimicrob Agents Chemother 1984; 26: 110–1

    Article  PubMed  CAS  Google Scholar 

  8. DuPont HL, Ericsson CD, Robinson A, et al. Current problems in antimicrobial therapy for bacterial enteric infection. Am J Med 1987; 82Suppl. 4A: 324–8

    PubMed  CAS  Google Scholar 

  9. Wise R, Lister O, McNulty CAM, et al. The comparative pharmacokinetics of five quinolones. J Antimicrob Chemother 1986; 18Suppl. 0: 71–81

    PubMed  CAS  Google Scholar 

  10. Wittke RR, Adam D. Diffusion ofpefloxacin in the biliary tract. Rev Infect Dis 1989; 11Suppl. 5: S1297–8

    Google Scholar 

  11. Van de Leur JJJPM, Vollaard EJ, Janssen AJHM, et al. Concentration of pefloxacin in feces during infection prophylaxis in neutropenic patients. Antimicrob Agents Chemother 1995; 39: 1182–4

    Article  PubMed  Google Scholar 

  12. Easmon CS, Crane JP. Uptake of ciprofloxacin by human neutrophils. J Antimicrob Chemother 1985; 16: 67–73

    Article  PubMed  CAS  Google Scholar 

  13. Easmon CS, Crane JP. Uptake of ciprofloxacin by macrophages. J Clin Path 1985; 38: 442–4

    Article  PubMed  CAS  Google Scholar 

  14. Easmon CS, Crane JP, Blowers A. Effect of ciprofloxacin on intracellular organisms: in-vitro and in-vivo studies. J Antimicrob Chemother 1986; 18 Suppl. 0: 43–8

    Google Scholar 

  15. Cartier MD, Scorneaux B, Zenebergh A, et al. Cellular uptake, localization and activity of fluoroquinolones in uninfected and infected macrophages. J Antimicrob Chemother 1990; 26(suppl B): 27–39

    Google Scholar 

  16. Desnottes JF, Diallo N. Comparative study of macrophagic uptake and action on phagocytosis of a macrolide (spiramycin) and a fluoroquinolone (pefloxacin). Pathol Biol 1990; 38: 281–5

    PubMed  CAS  Google Scholar 

  17. DuPont HL, Ericsson CD. Prevention and treatment of traveler’s diarrbea. N Engl J Med 1993; 328: 1821–7

    Article  PubMed  CAS  Google Scholar 

  18. DuPont HL. Quinolones in Salmonella typhi infection. Drugs 1993; 45Suppl. 3: 119–24

    Article  PubMed  Google Scholar 

  19. Gendrel O, Raymond J, Legall MA, et al. Use of pefloxacin after failure of initial antibiotic treatment in children with severe salmonellosis. Eur J Clin Microbiollnfect Dis 1993; 12: 209–11

    Article  CAS  Google Scholar 

  20. Dal Monte PR, Baroncini D. Pefloxacin in the treatment of acute gastroenteritis. 9th Mediterranean Congress of Chemotherapy, 1994: 87

    Google Scholar 

  21. Raymond J, Moulin F, Badoual J, et al. Eradication of convalescent-phase Salmonella carriage in children with two oral doses of pefloxacin. Eur J Clin Microbiollnfect Dis 1994; 13: 307–10

    Article  CAS  Google Scholar 

  22. Makwana MH, Malhan ST, Prabhu RN, et al. Pefloxacin in the treatment of typhoid fever in Indian patients. Curr Ther Res 1993; 54: 430–6

    Article  Google Scholar 

  23. Waiz A, Siddiqui M, Hossain M, et al. Efficacy and safety of pefloxacin in the treatment of typhoid fever. Drugs 1993; 45Suppl. 3: 396

    Article  Google Scholar 

  24. Ait-Khaled A, Zidane L, Amrane A, et al. A seven-day pefloxacin course for the treatment of typhoid fever in Algeria. Rev Infect Dis 1989; 11Suppl. 5: S1191–2

    Google Scholar 

  25. Kastanakis S, Vittorakis E. A comparative study ofpefloxacin in the treatment of typhoid fever in a hospital of Crete Island. 5th International Symposium on New Quinolones. 1994 Aug 25-27; Singapore: 115

  26. Hajji M, Mdaghri NE, Benbachir M, et al. Prospective randomized comparative trial of pefloxacin versus cotrimoxazole in the treatment of typhoid fever in adults. Eur J Clin Microbiol Infect Dis 1988; 7: 361–3

    Article  PubMed  CAS  Google Scholar 

  27. Gotuzzo E, Guerra JG, Benavente L, et al. Use of norfloxacin to treat chronic typhoid carriers. J Infect Dis 1988; 157: 1221–5

    Article  PubMed  CAS  Google Scholar 

  28. Ferreccio C, Morris Jr JG, Valdivieso C, et al. Efficacy of ciprofloxacin in the treatment of chronic typhoid carriers. J Infect Dis 1988; 157: 1235–9

    Article  PubMed  CAS  Google Scholar 

  29. Pichler HET, Diridl G, Stickler A, et al. Clinical efficacy of ciprofloxacin compared with placebo in bacterial diarrhea. Am J Med 1987; 82Suppl. 4A: 329–32

    PubMed  CAS  Google Scholar 

  30. Aserkoff B, Bennett JV. Effect of antibiotic therapy in acute salmonellosis on the fecal excretion of salmonellae. N Engl J Med 1969; 281: 636–40

    Article  PubMed  CAS  Google Scholar 

  31. Neill MA, Opal SM, Heelan J, et al. Failure of ciprofloxacin to eradicate convalescent fecal excretion after acute salmonellosis: experience during an outbreak in health care workers. Ann Intern Med 1991; 114; 195–9

    PubMed  CAS  Google Scholar 

  32. Christ W, Lehnert T, Ulbrich B. Specific toxicologic aspects of the quinolones. Rev Infect Dis 1988; 10Suppl.: S141–6

    Article  PubMed  CAS  Google Scholar 

  33. Shaad UB, Stoupis C, Wegwood J, et al. Clinical, radiologic and magnetic resonance monitoring for skeletal toxicity in pediatric patients with cystic fibrosis receiving a 3-month course of ciprofloxacin. Ped Infect Dis J 1991; 10: 723–9

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. St Luke’s Episcopal Hospital, 6720 Bertner Avenue, MC 1-164, Houston, Texas, 77030, USA

    Herbert L. DuPont

Authors
  1. Herbert L. DuPont
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

DuPont, H.L. Overview of Clinical Experience of Pefloxacin in Gastrointestinal Infections. Clinical Drug Investigation 11 (Suppl 2), 25–29 (1996). https://doi.org/10.2165/00044011-199600112-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-199600112-00006

Keywords

Search

Navigation